Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV + PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Kris Michael Mahadeo, Robert A. Baiocchi, Amer Beitinjaneh, Sridhar Chaganti, Sylvain Choquet, Daan Dierickx, Rajani Dinavahi, Laurence Gamelin, Armin Ghobadi, Norma Guzman-Becerra, Manher Joshi, Aditi Mehta, Sarah Nikiforow, Ran Reshef, Wei Ye, Susan Prockop

Blood (2022) 140 (Supplement 1): 10374–10376.

https://doi.org/10.1182/blood-2022-157766

Published: 2022

Journal Articles

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Susan Prockop, Kris Michael Mahadeo, Amer Beitinjaneh, Sylvain Choquet, Patrick Stiff, Ran Reshef, Gowri Satyanarayana, Saurabh Dahiya, Hema Parmar, Wei Ye, Laurence Gamelin, Rajani Dinavahi

Blood (2021) 138 (Supplement 1): 301.

https://doi.org/10.1182/blood-2021-147274

Published: 2021

Journal Articles

A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease (EBV + PTLD) after Failure of Rituximab or Rituximab and Chemotherapy

Susan Prockop, MD, Minoti Hiremath, MBBS, PhD, Wei Ye, PhD, Laurence Gamelin, MD, Willis Navarro, MD, Kris Michael Mahadeo, MD

Blood (2019) 134 (Supplement_1): 5326.

https://doi.org/10.1182/blood-2019-129277

Published: 2019

Journal Articles

Patient Co-Morbidity Profile Should Drive PI3K Inhibitor Selection for Relapsed Follicular Lymphoma

Farrukh T. Awan, MD MS, Rebecca J Chan, MD PhD, Wei Ye, PhD, Guan Xing, PhD, Caroline Roudet, PharmD, MBA, Bianca Ruzicka, PhD, Martin Dreyling, MD PhD, Pier Luigi Zinzani, MD, Ajay K. Gopal, MD

Blood (2018) 132 (Supplement 1): 5322.

https://doi.org/10.1182/blood-2018-99-110477

Published: 2018

Journal Articles

Idelalisib Plus Anti-CD20 Used Second Line Shows Improved PFS and Comparable Safety Compared to Later Line Therapy of Relapsed CLL

Jennifer R. Brown, MD PhD, Rebecca J Chan, MD PhD, Wei Ye, PhD, Guan Xing, PhD, Caroline Roudet, PharmD, MBA, Bianca Ruzicka, PhD, Susan M. O'Brien, MD

Blood (2018) 132 (Supplement 1): 5564.

https://doi.org/10.1182/blood-2018-99-110853

Published: 2018

Journal Articles

Survival Outcomes Following Idelalisib Interruption in the Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Shuo Ma, MD PhD, Rebecca J Chan, MD PhD, Wei Ye, PhD, Guan Xing, PhD, Carrie Ellen Brubaker, PhD, Caroline Roudet, PharmD, MBA, Bianca Ruzicka, PhD, Nina D. Wagner-Johnston, MD

Blood (2018) 132 (Supplement 1): 3149.

https://doi.org/10.1182/blood-2018-99-110655

Published: 2018

Journal Articles

Exposure-Response of Entospletinib (ENTO) for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

Sneha Gupta, PhD, Amy Meng, PhD, Shringi Sharma, PhD, Wei Ye, PhD, Jeffrey Silverman, PhD, Esteban M. Abella, MD, Anita Mathias, PhD

Blood (2017) 130 (Supplement 1): 1735.

https://doi.org/10.1182/blood.V130.Suppl_1.1735.1735

Published: 2017

Journal Articles

Evaluating the Efficacy, Safety, and Dose Dependent Activities of Entospletinib in Patients with Chronic Lymphocytic Leukemia

Jeffrey P. Sharman, MD, Kathryn S. Kolibaba, MD, Jose Azar, MD, Rama Balaraman, MD, Roger M. Lyons, MD, Mitchell R. Smith, MD PhD, Esteban Abella-Dominicis, MD, Wei Ye, PhD, Wen Shi, MD PhD, Thomas Giever, DO, Andres Forero-Torres, MD

Blood (2017) 130 (Supplement 1): 832.

https://doi.org/10.1182/blood.V130.Suppl_1.832.832

Published: 2017

Journal Articles

Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy

Ajay K. Gopal, Brad S. Kahl, Christopher R. Flowers, Peter Martin, Stephen M. Ansell, Esteban Abella-Dominicis, Brian Koh, Wei Ye, Paul M. Barr, Gilles A. Salles, Jonathan W. Friedberg

Blood (2017) 129 (22): 3037–3039.

https://doi.org/10.1182/blood-2016-12-757740

Published: 2017

Includes: Supplemental data

Journal Articles

A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor

Bing Xu, PhD, Yin Li, Kai Chen, Yong Zhou, Yiren Xiao, Manman Deng, Zhiwu Jiang, Wei Ye, Xinru Wei, Xiangmeng Wang, Jie Li, Jiabao Liang, Zhongxin Zheng, Yao Yao, MD, Weiguang Wang, Peng Li, PhD

Blood (2015) 126 (23): 4925.

https://doi.org/10.1182/blood.V126.23.4925.4925

Published: 2015

Journal Articles

Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy

Ajay K Gopal, MD, Brad S Kahl, MD, Christopher Flowers, MD, Peter Martin, MD, Brian K Link, MD, Stephen Ansell, MD PhD, Wei Ye, Brian Koh, MD, Steve Abella, MD, Paul M. Barr, MD, Gilles A. Salles, MD PhD, Jonathan W. Friedberg, MD MMSc

Blood (2015) 126 (23): 2744.

https://doi.org/10.1182/blood.V126.23.2744.2744

Published: 2015

Journal Articles

Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Peter Martin, MD, Armando Armas, MD, Ajay K Gopal, MD, Emmanuel Gyan, MD PhD, Nina D. Wagner-Johnston, MD, Jan Walewski, MDPhDProf, Steve Abella, MD, Wei Ye, Betsy Philip, Bess Sorenson, Sven de Vos, MD PhD

Blood (2015) 126 (23): 1543.

https://doi.org/10.1182/blood.V126.23.1543.1543

Published: 2015

Journal Articles

Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma

Robert Chen, MD, Paul Frankel, PhD, Leslie Popplewell, MD, Tanya Siddiqi, MD, Wei Ye, Joel Conrad, BS, Michelle Mott, RN, Auayporn Nademanee, MD, Myo Htut, MD, Stephen J. Forman, MD, Mark Kirschbaum, MD

Blood (2013) 122 (21): 4398.

https://doi.org/10.1182/blood.V122.21.4398.4398

Published: 2013

NARROW

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease (EBV + PTLD) after Failure of Rituximab or Rituximab and Chemotherapy

Patient Co-Morbidity Profile Should Drive PI3K Inhibitor Selection for Relapsed Follicular Lymphoma

Idelalisib Plus Anti-CD20 Used Second Line Shows Improved PFS and Comparable Safety Compared to Later Line Therapy of Relapsed CLL

Survival Outcomes Following Idelalisib Interruption in the Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Exposure-Response of Entospletinib (ENTO) for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

Evaluating the Efficacy, Safety, and Dose Dependent Activities of Entospletinib in Patients with Chronic Lymphocytic Leukemia

Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy

A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor

Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy

Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only